Department of Pathology, Manisa Celal Bayar University, Faculty of Medicine, MANISA, TURKEY.
Turk Patoloji Derg. 2021;37(2):130-138. doi: 10.5146/tjpath.2020.01514.
To evaluate the quantity of tumor-associated macrophages (TAMs) in cases of Hodgkin Lymphoma of classical type (cHL), and to reveal possible associations between TAM intensity and latent Epstein-Barr virus (EBV) infection, overall survival, progression-free survival, prognostic indices, and clinicopathological parameters.
A total 46 cases of cHL with complete clinical records were selected and re-evaluated histopathologically. Staining for CD68 (PG-M1; KP1 clones) and CD163 was evaluated and the cut-off values were defined. Also, all cases were evaluated using the chromogen in situ hybridization (CISH) method with EBER (Epstein-Barr virus-encoded RNA) probes for the presence of possible EBV infection.
It was found that high expression levels of PG-M1 and high International Prognostic Scores (IPS) were associated with shortened overall survival (p=0.047, p=0.013). Cases with 2 or less areas of nodal region involvement were observed to have longer progression-free survival period (p=0.043). Higher expression levels of CD68 PG-M1, CD68 KP1, and CD163 were found to show significant associations with the presence of some clinical parameters such as the presence of B symptoms, spleen involvement, and the presence of EBV infection.
Our findings suggest that increase of PG-M1+ TAM is associated with shortened overall survival, while higher expressions of all immunohistochemical markers are statistically significantly associated with the presence of EBV infection and clinical parameters mentioned above. These findings indicate that highlighting the TAM rate via macrophage markers in cases of cHL could be helpful in determining the prognostic risk groups and the relevant results should be mentioned in pathology reports.
评估经典型霍奇金淋巴瘤(cHL)中肿瘤相关巨噬细胞(TAMs)的数量,并揭示 TAM 强度与潜伏性 EBV 感染、总生存期、无进展生存期、预后指标以及临床病理参数之间的可能关联。
选择了 46 例具有完整临床记录的 cHL 病例,并进行了重新组织病理学评估。对 CD68(PG-M1;KP1 克隆)和 CD163 的染色进行了评估,并定义了临界值。同时,使用显色原位杂交(CISH)方法和 EBER(Epstein-Barr 病毒编码 RNA)探针评估所有病例是否存在潜在 EBV 感染。
发现 PG-M1 高表达水平和高国际预后评分(IPS)与总生存期缩短相关(p=0.047,p=0.013)。观察到 2 个或更少区域的淋巴结受累病例具有更长的无进展生存期(p=0.043)。CD68 PG-M1、CD68 KP1 和 CD163 的高表达水平与某些临床参数的存在显著相关,例如 B 症状、脾脏受累和 EBV 感染的存在。
我们的研究结果表明,PG-M1+TAM 的增加与总生存期缩短相关,而所有免疫组织化学标志物的高表达与 EBV 感染和上述临床参数的存在具有统计学相关性。这些发现表明,在 cHL 病例中通过巨噬细胞标志物突出 TAM 率可能有助于确定预后风险组,相关结果应在病理报告中提及。